Cryoport and Minaris Partner for Regenerative Medicine Logistics

• Cryoport and Minaris announce strategic partnership for regenerative medicine.

• Logistics Collaboration aims to provide integrated services for cell and gene therapies.

Cryoport, a provider of supply chain solutions for the life sciences, has partnered with Minaris Regenerative Medicine Co., Ltd., a global contract development and manufacturing organization for cell and gene therapies. The strategic partnership aims to offer fully integrated logistics and manufacturing services to biotechnology and pharmaceutical companies for regenerative medicine products, supporting the advancement of cell and gene therapies.

The collaboration leverages Cryoport’s extensive experience in meeting the logistics needs of the life sciences industry with Minaris’ expertise in contract manufacturing of regenerative medicine products, including stem cells, gene therapy, biomaterials, and engineered tissue.

Jerrell Shelton, CEO of Cryoport, highlighted the significance of the partnership, stating, “We look forward to partnering with Minaris to provide cohesive supply chain solutions and manufacturing services for regenerative medicine products, starting from the collection of cells and tissues all the way to the delivery of these critical products and services to patients.”

Dr. Hiroto Bando, CEO of Minaris, emphasized the importance of secure transport and quality assurance for regenerative medicine products. He added, “By partnering with Cryoport, a best-in-class company with considerable resources in these areas, we will collaborate to provide high-quality services tailored to the exact needs of our customers.”

The partnership, although initiated with Minaris’ Japan-based branch, aims to provide services to customers across the entire Minaris group, ensuring a comprehensive and tailored approach to supporting the advancement of regenerative medicine and cell and gene therapies.